Back to User profile » Professor Alberto Papi
Papers published by Professor Alberto Papi:
Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS
Price D, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Nudo E, Carter V, Skinner D, Vella R, Soriano JB, Kots M, Georges G
Pragmatic and Observational Research 2024, 15:1-16
Published Date: 20 January 2024
A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD
Tse G, Emmanuel B, Ariti C, Bafadhel M, Papi A, Carter V, Zhou J, Skinner D, Xu X, Müllerová H, Price D
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2565-2580
Published Date: 15 November 2023
Symptom Burden, Health Status, and Productivity in Patients with Uncontrolled and Controlled Severe Asthma in NOVELTY
Ding B, Chen S, Srivastava D, Quinton A, Cook W, Papi A, Reddel HK
Journal of Asthma and Allergy 2023, 16:611-624
Published Date: 11 June 2023
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset [Corrigendum]
Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2451-2452
Published Date: 3 October 2022
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset
Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1909-1920
Published Date: 22 August 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:489-490
Published Date: 7 March 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:355-370
Published Date: 15 February 2022
Burden of Pertussis in Individuals with a Diagnosis of Asthma: A Retrospective Database Study in England
Bhavsar A, Aris E, Harrington L, Simeone JC, Ramond A, Lambrelli D, Papi A, Boulet LP, Meszaros K, Jamet N, Sergerie Y, Mukherjee P
Journal of Asthma and Allergy 2022, 15:35-51
Published Date: 11 January 2022
Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program
Campisi R, Crimi C, Nolasco S, Beghè B, Antonicelli L, Guarnieri G, Scichilone N, Porto M, Macchia L, Scioscia G, Foschino Barbaro MP, Papi A, Crimi N
Journal of Asthma and Allergy 2021, 14:575-583
Published Date: 27 May 2021
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
Pavord ID, Siddiqui S, Papi A, Corren J, Sher LD, Bardin P, Langton D, Park HS, Rice MS, Deniz Y, Rowe P, Staudinger HW, Patel N, Ruddy M, Graham NMH, Teper A
Journal of Asthma and Allergy 2020, 13:701-711
Published Date: 16 December 2020
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD
Ming SWY, Haughney J, Ryan D, Small I, Lavorini F, Papi A, Singh D, Halpin DMG, Hurst JR, Patel S, Ochel M, Kocks J, Carter V, Hardjojo A, Price DB
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:3093-3103
Published Date: 26 November 2020
The Burden of Self-Reported Rhinitis and Associated Risk for Exacerbations with Moderate-Severe Asthma in Primary Care Patients
Kritikos V, Price D, Papi A, Infantino A, Ställberg B, Ryan D, Lavorini F, Chrystyn H, Haughney J, Lisspers K, Gruffydd-Jones K, Román Rodríguez M, Høegh Henrichsen S, van der Molen T, Carter V, Bosnic-Anticevich S
Journal of Asthma and Allergy 2020, 13:415-428
Published Date: 6 October 2020
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:531-546
Published Date: 28 February 2019
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:3971-3981
Published Date: 12 December 2018
The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study
Singh D, Vezzoli S, Petruzzelli S, Papi A
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3263-3271
Published Date: 3 November 2017
Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2917-2928
Published Date: 6 October 2017
Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
Papi A, Dokic D, Tzimas W, Mészáros I, Olech-Cudzik A, Koroknai Z, McAulay K, Mersmann S, Dalvi PS, Overend T
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1961-1971
Published Date: 5 July 2017
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD
Papi A, Jones PW, Dalvi PS, McAulay K, McIver T, Dissanayake S
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2431-2438
Published Date: 9 November 2015
Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
Scichilone N, Benfante A, Morandi L, Bellini F, Papi A
Patient Related Outcome Measures 2014, 5:153-162
Published Date: 27 November 2014